Report Store Get Proposal

Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

Home Blog Rare diseases 13

Rare Diseases

pharma-happenings-for-merck-abbvie-incyte-aprea-eisai

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Merck’s Keytruda Approval; Abbvie’s Venetoclax; Aprea’s Eprenetapopt; CRL to Incyte’s Retifanlimab; Keytruda/Lenvima for Endometrial Cancer

FDA Approves Keytruda in Both Adjuvant and Neoadjuvant Setting in High-Risk Early-Stage TNBC In July 2021, the US FDA approved pembrolizumab (Keytruda) for high-risk, early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment and then continued as a single agent as adjuvant treatment after surgery. This approval was based on Phase III KEYNOTE-522 trial (NCT03036488) and became the first immunotherapy regimen to be approved in high-risk early-stage TNBC, marking a milestone for breast cancer patients. Earlier in February 2021, the agency rejected Merck’s application to approve the drug for this population and requested...

Explore More...

MEDICAL MARIJUANA

What can be the scope of Medical Marijuana?

Multiple Sclerosis

Notizia

autism

Boys are more likely to have autism!

Multiple myeloma market

Multiple Myeloma Day

common cold

ColdZyme inactivates viruses; Med for rare genetic disease; Common oral bacteria accelerate Colon cancer; CEPI and CureVac to develop an mRNA vaccine; Celastrol’s effectiveness

Cost ineffective Orphan Drugs limit the access

Rare Disease Day

Rare Disease Day

Kidney Cancer

Notizia

Peloton Therapeutics

Neurogene raises $68.5M; AbbVie and Teneobio sign deal; 5AM Ventures nets

Myasthenia gravis (MG)

Myasthenia Gravis

merck

BridgeBio bags $299M; Immunochina receives $20M; Attune raises; Wren receives $23M

Oncology

Notizia

artificial intelligence

Artificial Intelligence face-scanning app spots signs of rare genetic disorders

vedanta

Vedanta raises; Relay Therapeutics reels in; Gene therapy for SMA

Gilead

Tetra, Shionogi sign deal; Amgen remunerates; Gilead’s fibrotic disease deal

alzheimer's

Lilly remunerates AC Immune; Akero adds $70M; Ra Pharma $100M

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Daily

Weekly

Monthly